Stability indicating method development for simultaneous determination of ezetimibe and atorvastatin in dosage form by RP-HPLC

Simple, specific, economical and precise high performance liquid chromatographic method for the simultaneous determination of ezetimibe and Atorvastatin in API (active pharmaceutical ingredient) and formulation has been developed and validated. Chromatography was carried out at 30◦C on a prepacked Zorbax SB C18 (5 mm, 250 x 4.6 mm) column with the 0.02 M potassium dihydrogen phosphate: Acetonitrile: Methanol (10:40:50, v/v/v) was used as the mobile phase. The UV detection was carried at 236 nm. The results obtained showed good agreement with the declared contents. Ezetimibe and Atorvastatin separated in less than 10 mins with good resolution and minimal tailing and without interference of excipients. The retention times of ezetimibe and Atorvastatin were 5.7 min and 9.1 min, respectively. The method was linear in the range of 5–50 μg/ml for Ezetimibe concentration with a correlation co-efficient 0.9992 and in the range 5–60 μg/ml for Atorvastatin concentrations having correlation coefficient 0.9994 and the recovery was 99-102%. The method was validated according to ICH guidelines and the acceptance criteria for accuracy, precision, linearity, specificity and system suitability were met in all cases. The proposed method can be used for quantitative determination of Ezetimibe and Atorvastatin combination from API and formulations.

Author(s): Praveen Kumar and Yusra Ahmad

Abstract | PDF

Share This Article